While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

GLP-1 receptor agonists do not affect cardiovascular, kidney, or safety outcomes regardless of SGLT2 inhibitor use in patients with type 2 diabetes.

About The Study: Prescribing for both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors in a type 1 diabetes (T1D) population identified in a ...

Prescriptions of GLP-1RAs and SGLT2 inhibitors in type 1 diabetes patients rose from 2010 to 2023, especially among those ...

Additionally, nearly one-quarter had heart failure and 49% were taking an sodium-glucose cotransporter 2 (SGLT2) inhibitor at ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Polygenic risk scores are significantly less predictive of opioid dependence risk than environmental factors—in particular, education level and annual household income, according to new study results.

TheracosBio has entered a partnership with BAMCO Africa to deliver BRENZAVVY (bexagliflozin) to patients in sub-Saharan ...

A large study of veterans with type 2 diabetes finds better short-term kidney outcomes with use of SGLT2 inhibitors vs GLP-1 receptor agonists.

Lexicon to receive an upfront payment of $25 million and the potential for contingent regulatory and commercial milestone paymentsTHE WOODLANDS, Texas, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX ...